InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,314.19
(
0.17%
)
Post# of 253171
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 213939

Thursday, 09/28/2017 11:57:06 AM

Thursday, September 28, 2017 11:57:06 AM

Post# of 253171
Re: ABBV-AMGN Humira settlement

The key date is 1/31/23, when ABBV has permitted AMGN to launch Amgevita (Humira FoB) in the US market.

Other Humira-FoB companies such as MNTA will presumably be able to get the same deal, but will they take it?

MNTA’s CEO has asserted that MNTA has a workaround for ABBV’s US Humira patents that pertain to formulation, specifically, which is something that AMGN presumably does not have.

In any case, we probably won’t know for at least a year (when FDA approves MNTA’s M923 Humira FoB) whether MNTA will opt to defend or settle.

p.s. CHRS +3%, MNTA +2% today.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up